220 related articles for article (PubMed ID: 19877891)
1. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
[TBL] [Abstract][Full Text] [Related]
2. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
Yuan S; Shi C; Han W; Ling R; Li N; Wang T
Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341
[TBL] [Abstract][Full Text] [Related]
3. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
4. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
5. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
6. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
7. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
8. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.
Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G
Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.
Vasilevko V; Ghochikyan A; Sadzikava N; Petrushina I; Tran M; Cohen EP; Kesslak PJ; Cribbs DH; Nicolson GL; Agadjanyan MG
Clin Exp Metastasis; 2003; 20(6):489-98. PubMed ID: 14598882
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
13. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
Dols A; Smith JW; Meijer SL; Fox BA; Hu HM; Walker E; Rosenheim S; Moudgil T; Doran T; Wood W; Seligman M; Alvord WG; Schoof D; Urba WJ
Hum Gene Ther; 2003 Jul; 14(11):1117-23. PubMed ID: 12885350
[TBL] [Abstract][Full Text] [Related]
15. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine.
Hu B; Wang J; Guo Y; Chen T; Ni W; Yuan H; Zhang N; Xie F; Tai G
Int Immunopharmacol; 2016 Apr; 33():108-18. PubMed ID: 26896668
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
Deng YH; He HY; Zhang FJ
Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]